Bausch Health Companies Inc. Common Stock (BHC)
Stock · NYSE · Health Care
$6.29as of 10/16/2026
Price chart
Active signals
BHC Signal Track Record
How signals performed across all stocks →What BHC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -0.4% | 46% | September 2, 2026 |
| Bollinger Band Breakdown | 22 | +0.9% | 64% | September 11, 2026 |
| Bollinger Band Breakout | 21 | +0.4% | 57% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 19 | -1.2% | 42% | September 28, 2026 |
| Any 20-session window (baseline) | -0.8% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BHC
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry p…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 20,300
- Website
- www.bauschhealth.com/
Fundamentals
- 1-day range
- $6.2$6.39
- Market cap
- $2.21B
- P/E (trailing)
- —
- P/E (forward)
- 1.47
- EPS (trailing)
- $-2.96
- Dividend yield
- —
- Beta
- 0.65
- Avg. volume
- 3.27M
- Ex-dividend date
- November 10, 2010
How Bausch Health Companies Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Bausch Health Companies Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- SLSSELLAS Life Sciences Group Inc. Common Stock$9.98▼ 11.99%Market cap $2.18BP/E —$1.39$15.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| SLS SELLAS Life Sciences Group Inc. Common Stock | $2.18B | — | $9.98 | ▼ 11.99% | $1.39$15.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Bausch + Lomb Stock Falling Monday?benzinga · 10/12/2026
- Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026Yahoo · 10/6/2026
- The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health CompaniesYahoo · 10/5/2026
- 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeYahoo · 10/2/2026
- Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 PicksYahoo · 9/30/2026
- Zacks Value Investor Highlights: FOXF, BHC and QNSTYahoo · 9/28/2026
- Screening for Hidden Gem Stocks Under $20Yahoo · 9/24/2026
- Tracking John Paulson's Paulson & Company Portfolio: Q2 2026 UpdateSeekingAlpha · 9/22/2026
- Best Value Stocks to Buy for September 22ndYahoo · 9/22/2026
Insider Activity
Insider Actions →- WECHSLER AMY B · September 30, 2026 · Grant1.2K @ $5.83
- John Paulson · September 30, 2026 · Grant10.7K @ $5.83
- LEUNG SANDRA · September 30, 2026 · Grant5.8K @ $5.83
- Lenar Aimee J. · August 19, 2026 · Sale36.8K @ $7.03
- Lenar Aimee J. · July 17, 2026 · Tax Withholding5.3K @ $4.83
- Lenar Aimee J. · July 15, 2026 · Tax Withholding23.4K @ $4.89
- LEE STEVEN HYOSIG · July 14, 2026 · Tax Withholding3.1K @ $4.75
- WECHSLER AMY B · June 30, 2026 · Grant1.4K @ $4.93
- John Paulson · June 30, 2026 · Grant12.7K @ $4.93
- LEUNG SANDRA · June 30, 2026 · Grant6.8K @ $4.93
- Frank D. Lee · May 22, 2026 · Grant45.9K
- GOETTLER MICHAEL · May 22, 2026 · Grant45.9K
- ROBERTS EIRY · May 22, 2026 · Grant45.9K
- Sarah B. Kavanagh · May 22, 2026 · Grant45.9K
- WECHSLER AMY B · May 22, 2026 · Grant45.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 234.38M
- Total value held
- $1.24B
- Institutional holders
- 226
- Unknown73.26M
- Unknown34.67M
- Unknown11.36M
- Unknown8.99M
- Unknown8.00M
- Unknown7.40M
- Unknown6.00M
- Unknown5.24M
- Unknown5.21M
- Unknown5.00M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance
Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.